#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | #LCSM Chat @lcsmchat RT @BrendonStilesMD: The topic doesn’t get 🔥 than this. Join our #immunotherapy #lcsm chat tonight in 7 minutes, no matter what type of cancer you are interested in. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: One of my oncologists told me yesterday that he gets annoyed that I talk about medical oncology so much. Here it comes. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Hope some #lcsm tweeps, peeps, and friends are out there! |
 | Brendon Stiles @BrendonStilesMD OK...I have 8PM ET. Let's get started. #lcsm |
| Brendon Stiles @BrendonStilesMD Welcome to #LCSM Chat! Our topic tonight is “Immunotherapy–the ultimate personalized therapy” #lcsm |
 | Kathleen Skambis @KathleenSkambis #lcsm |
 | Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD Hey Brendon! Thanks for moderating tonight's chat. #lcsm |
 | Faces of Lung Cancer @LungCancerFaces Deana Hendrickson in Los Angeles here. Excited about tonight's chat! #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell Never. Although I do like to drop some knowledge. But I know I am annoying. #lcsm |
| Brendon Stiles @BrendonStilesMD What is better than allowing your own immune system to fight your cancer? #lcsm |
 | Sara Whitlock @sjwhitlock Sara here! #lcsm |
| Brendon Stiles @BrendonStilesMD More info at https://t.co/Lx9qF406C9 #lcsm |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. #lcsm https://t.co/9dM8uLyawM |
| Brendon Stiles @BrendonStilesMD You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | Vamsi Velcheti, MD @VamsiVelcheti #LCSM @VamsiVelchev reporting on time for #lCSMchat @BrendonStilesMD |
| Brendon Stiles @BrendonStilesMD One way to join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm #lcsm |
| Faces of Lung Cancer @LungCancerFaces @sjwhitlock Hi Sara! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Janet Freeman-Daily in Seattle, enjoying the warmer, drier spring. #lcsm |
 | Peggy Dennis @peggyddennis #LCSM Happiness is......great scan results! Almost 2 years out. Looking forward to tonights discussion. |
| Brendon Stiles @BrendonStilesMD Holy smokes!!!! A lot of my favorites here already! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @KathleenSkambis I see you Kathleen! #lcsm |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Not a medical oncologist! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @peggyddennis Congrats Peggy! #lcsm |
| Brendon Stiles @BrendonStilesMD Thanks goodness it looks like we have some real experts here -pathologists, oncologists, patients. #lcsm |
 | NCI Cancer Stats @NCICancerStats Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: https://t.co/IlNVjtpQ3z #LCSM https://t.co/m1DtoSh8DP |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD Gotta have a pathologist! #lcsm |
 | Flemming Rasmussen @fgrazz Listening in from Halifax, NS #lcsm |
| Janet Freeman-Daily @JFreemanDaily Welcome Kathleen, Sara, Tim, Vamsi, Peggy and Jeannine! #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD having supercharged engineered T-cells # need CARs and TRUCKs for solid tumors #LCSM |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell Nate Pennell reporting in from Cleveland! #lcsm |
| Brendon Stiles @BrendonStilesMD @VamsiVelchev Awesome. Thanks for joining. #lcsm |
 | Dr. David Tom Cooke @DavidCookeMD Did someone say @lcsmchat ? #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy, @LungCancerFaces #lcsm https://t.co/tVfBqH1k1I |
 | Paula Ashton @paulalv #LCSM hi everyone. Paula in hotter than heck Las Vegas |
| Brendon Stiles @BrendonStilesMD Power squad all around. #lcsm |
 | It's me! @JohnLPender Checking in. #lcsm |
 | DrSchiaffino (She/Her/Ella) @mexicolindo RT @NCICancerStats: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: https://t.co/IlNVjtpQ3z #LCSM https://t.co/m1DtoSh8DP |
 | Denise Cutlip @dennycee Hello from sunny Michigan. #lcsm |
| Flemming Rasmussen @fgrazz @BrendonStilesMD I'm none of those...but I still love being here #LCSM |
| Brendon Stiles @BrendonStilesMD In this week’s chat we hope to unlock the mystery of immunotherapy: why, who, what, and when? #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi Fleming, Nate and David! #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat |
 | H. Jack West, MD @JackWestMD Hi, #LCSM chat folks. I'm a Seattle-based med onc with a major focus on lung cancer, looking forward to great discussion of how immunotherapy is changing treatment landscape. |
| Brendon Stiles @BrendonStilesMD The pace of new immunotherapy drugs and trials is hard to keep up with for everyone! #lcsm |
 | SWOG Cancer Research Network @SWOG RT @NCICancerStats: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: https://t.co/IlNVjtpQ3z #LCSM https://t.co/m1DtoSh8DP |
| Brendon Stiles @BrendonStilesMD @fgrazz Gotta have the scientist! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Good to see you, Denise and Jack! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #PatientsFirst #lcsm https://t.co/ROGJGXL24O |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Brendon Stiles @BrendonStilesMD Fortunately, we now have many immunotherapy tools for lung cancer! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: What is better than allowing your own immune system to fight your cancer? #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Got some surgical presence tonight! @DavidCookeMD @BrendonStilesMD #lcsm |
| Brendon Stiles @BrendonStilesMD Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| #LCSM Chat @lcsmchat RT @peggyddennis: #LCSM Happiness is......great scan results! Almost 2 years out. Looking forward to tonights discussion. |
 | Michele @rants_by_egg #lcsm successfully treated immunotherapy patient here |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Not a medical oncologist! #lcsm |
| Brendon Stiles @BrendonStilesMD If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @n8pennell: Got some surgical presence tonight! @DavidCookeMD @BrendonStilesMD #lcsm |
| Brendon Stiles @BrendonStilesMD @rants_by_egg A true expert! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Thanks goodness it looks like we have some real experts here -pathologists, oncologists, patients. #lcsm |
| Brendon Stiles @BrendonStilesMD I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @rants_by_egg: #lcsm successfully treated immunotherapy patient here |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
 | Joni Fowler, PharmD, BCPP @jfowlerpharmd @BrendonStilesMD Don’t forget the pharmacist! 🙋🏼♀️ #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD PD-L1 is my middle name! #lcsm https://t.co/LRtt3olKxV |
| Janet Freeman-Daily @JFreemanDaily Welcome to John, Paula, and Michele! #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat |
| Brendon Stiles @BrendonStilesMD I would like to disclose conflicts – have worked with @merck and @astrazeneca and my wife worked @pfizer and now @ppdCRO I like to think I have no bias. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: The pace of new immunotherapy drugs and trials is hard to keep up with for everyone! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Fortunately, we now have many immunotherapy tools for lung cancer! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi Joni! I think you're our first pharmacist in #LCSM Chat. |
| #LCSM Chat @lcsmchat RT @rants_by_egg: #lcsm successfully treated immunotherapy patient here |
| Brendon Stiles @BrendonStilesMD @jfowlerpharmd Critical to have a pharmacist! #lcsm |
 | Fred Gray @fcgiii Hello #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Any rad oncs tonight to explain abscopal effect? If not, we’re going with “magic” in the why column! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: PD-L1 is my middle name! #lcsm https://t.co/LRtt3olKxV |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I would like to disclose conflicts – have worked with @merck and @astrazeneca and my wife worked @pfizer and now @ppdCRO I like to think I have no bias. #lcsm |
| Brendon Stiles @BrendonStilesMD T1: How does immunotherapy work and what are the side effects? #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hey Fred! Good to see you. @fcgiii #lcsm |
 | Mark Lewis @marklewismd Hello #LCSM colleagues. I am a GI medical oncologist who is venturing timidly above the diaphragm for once, tempted by all the wonderful -mabs you're discussing. Good evening @lcsmchat |
| #LCSM Chat @lcsmchat RT @n8pennell: Any rad oncs tonight to explain abscopal effect? If not, we’re going with “magic” in the why column! #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell "magic" is a good start. #lcsm |
| Denise Cutlip @dennycee @marklewismd Welcome! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Consulted with AstraZeneca, Lilly, and Regeneron #COI #lcsm |
| #LCSM Chat @lcsmchat Welcome! Remember to add #lcsm to your tweets. https://t.co/SVcFtpvjLy |
| Brendon Stiles @BrendonStilesMD T1. “Immunotherapy” is a broad topic - includes vaccines, antibodies, & nonspecific therapies that boost immune system #lcsm |
| #LCSM Chat @lcsmchat RT @marklewismd: Hello #LCSM colleagues. I am a GI medical oncologist who is venturing timidly above the diaphragm for once, tempted by all the wonderful -mabs you're discussing. Good evening @lcsmchat |
| Dr. David Tom Cooke @DavidCookeMD A1 It prevents your own immune system from being turned off by tumor cells, so your immune system can now fight cancers such as #lungcancer #LCSM |
| Brendon Stiles @BrendonStilesMD Conflicts with pharma for me too in previous tweet #lcsm |
| Janet Freeman-Daily @JFreemanDaily @n8pennell Hey Matt Katz (@subatomicdoc) -- we need you tonight to tell us about abscopal effect! #lcsm |
 | KC Dill @kasedill Checking in from Texas #lcsm |
| Brendon Stiles @BrendonStilesMD @marklewismd @lcsmchat thanks for joining! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. “Immunotherapy” is a broad topic - includes vaccines, antibodies, & nonspecific therapies that boost immune system #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Immunotherapy generally uses drugs to stimulate your own immune system to work better and attack cancer cells. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: Consulted with AstraZeneca, Lilly, and Regeneron #COI #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. “Immunotherapy” is a broad topic - includes vaccines, antibodies, & nonspecific therapies that boost immune system #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: A1 It prevents your own immune system from being turned off by tumor cells, so your immune system can now fight cancers such as #lungcancer #LCSM |
| Brendon Stiles @BrendonStilesMD T1. “Checkpoint inhibitors” are most commonly used in lung cancer. These drugs release the “brakes” from the immune system so it can attack cancer cells. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @n8pennell Hey Matt Katz (@subatomicdoc) -- we need you tonight to tell us about abscopal effect! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Immunotherapy generally uses drugs to stimulate your own immune system to work better and attack cancer cells. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @kasedill Hi KC! #lcsm |
| Brendon Stiles @BrendonStilesMD T1. In lung cancer, most of focus has been on the interaction of PD-L1 (from cancer cells) and PD1 made by T cells #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. Immunotherapy generally uses drugs to stimulate your own immune system to work better and attack cancer cells. #lcsm |
 | Cafer BAŞ @brtmnbs #lcsm |
| Dr. David Tom Cooke @DavidCookeMD Think of "checkpoint" as the guard station with the security guard checking your ID and credentials. It's not the point where you realize you are going to win the chess game in another two moves. #LCSM https://t.co/SVdTT4tmdI |
| Brendon Stiles @BrendonStilesMD T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: Some immunotherapies "take the brakes off" the immune system so it can go after certain types of cancer cells. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @n8pennell The idea of abscopal effect predates IO and is a misnomer in the IO context- we should stop referring to abscopal effect... it is actually “in-vivo immunization” #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm |
| Peggy Dennis @peggyddennis Peggy from Denver checking in. Don't need yet but Immuno could be next line so very interested in this discussion. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD This is not chemotherapy or molecular therapy. #lcsm https://t.co/V0jItog67y |
| Janet Freeman-Daily @JFreemanDaily @RedGia No problem--welcome! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. “Checkpoint inhibitors” are most commonly used in lung cancer. These drugs release the “brakes” from the immune system so it can attack cancer cells. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. In lung cancer, most of focus has been on the interaction of PD-L1 (from cancer cells) and PD1 made by T cells #lcsm |
| Janet Freeman-Daily @JFreemanDaily @brtmnbs We see you -- welcome! #lcsm |
| Dr. David Tom Cooke @DavidCookeMD #LCSM #immunotherapy https://t.co/6SPm8e3Fvz |
 | Krishna Soujanya Gunturu MD @kgunturuMD Hi, checking in #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DavidCookeMD: Think of "checkpoint" as the guard station with the security guard checking your ID and credentials. It's not the point where you realize you are going to win the chess game in another two moves. #LCSM https://t.co/SVdTT4tmdI |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm |
| Brendon Stiles @BrendonStilesMD Here are different types: #lcsm https://t.co/jnehLpt5uy |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T1: Magic! No, kidding! Immune checkpoints help prevent auto(self)immunity, but Cancer takes advantage of that to escape the immune system since it is technically “you”, no matter how abnormal #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T1 cont: so by blocking these checkpoints (like CTLA-4 and PD-1/PDL1) we stop that from happening and the immune system can attack #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: Think of "checkpoint" as the guard station with the security guard checking your ID and credentials. It's not the point where you realize you are going to win the chess game in another two moves. #LCSM https://t.co/SVdTT4tmdI |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DavidCookeMD: #LCSM #immunotherapy https://t.co/6SPm8e3Fvz |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Some immunotherapies "take the brakes off" the immune system so it can go after certain types of cancer cells. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @n8pennell The idea of abscopal effect predates IO and is a misnomer in the IO context- we should stop referring to abscopal effect... it is actually “in-vivo immunization” #LCSM |
| Janet Freeman-Daily @JFreemanDaily @marklewismd Good to see you! #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Side effects are generally less than with chemotherapy, but are unique and include many “itis” problems. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: This is not chemotherapy or molecular therapy. #lcsm https://t.co/V0jItog67y |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @n8pennell: T1: T1: Magic! No, kidding! Immune checkpoints help prevent auto(self)immunity, but Cancer takes advantage of that to escape the immune system since it is technically “you”, no matter how abnormal #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @n8pennell: T1 cont: T1 cont: so by blocking these checkpoints (like CTLA-4 and PD-1/PDL1) we stop that from happening and the immune system can attack #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @VamsiVelchev: @n8pennell The idea of abscopal effect predates IO and is a misnomer in the IO context- we should stop referring to abscopal effect... it is actually “in-vivo immunization” #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy |
| Kathleen Skambis @KathleenSkambis @VamsiVelchev @n8pennell #lcsm what is IO? |
| Brendon Stiles @BrendonStilesMD T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm |
| Janet Freeman-Daily @JFreemanDaily @peggyddennis Hi Peggy! #lcsm |
 | Diane 🧚🏻♀️ @diianeee Lcsm #lcsm |
| Brendon Stiles @BrendonStilesMD T1. As these drugs are more commonly used, doctors need to be more aware of side effects. https://t.co/UcSfnXz1qC #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD And can occasionally be severe. #lcsm https://t.co/29WBTHxTHu |
| Flemming Rasmussen @fgrazz RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy |
| Janet Freeman-Daily @JFreemanDaily "IO" is a shorthand way to say "immunotherapy" @KathleenSkambis @VamsiVelchev @n8pennell #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm |
 | Lung Cancer #1 cancer killer of women @VirginiaMByrne Hi! #lcsm |
| Dr. David Tom Cooke @DavidCookeMD Has anyone in the #LCSM community experienced #Immunotherapy side affects, and if so what were/ are they? #LCSM https://t.co/PxzjRlkq0k |
| Faces of Lung Cancer @LungCancerFaces @krishna_gunturu Welcome! #lcsm |
| Michele @rants_by_egg #lcsm fatigue is my only side effect, easy to push through...but fatigue could be due to age, confounding variable |
| H. Jack West, MD @JackWestMD @DavidCookeMD Good analogy: Here a tumor w/high PD-L1 is like a thief who has fake credentials that make immune system more complacent about presuming he should be left alone. Removing credentials & forcing closer look by guard -> better recognition of who belongs & who doesn't. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #lcsm https://t.co/KdUH8CEP5D |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD Tumors need to have 💡 on to have immune response i.e respond to checkpoint inhibitors unfortunately most don’t have the 💡 on and need more to make them response to immunotherapy #LCSM |
| Denise Cutlip @dennycee T1: I’ve had friends develop arthritis, thyroid and pancreas issues shortly after starting pembrolizumab. #lcsm |
 | colleen ziegler @ZieglerColleen HI, Colleen joining #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: #LCSM #immunotherapy https://t.co/6SPm8e3Fvz |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: "IO" is a shorthand way to say "immunotherapy" @KathleenSkambis @VamsiVelchev @n8pennell #lcsm |
 | Sevtap Savas, PhD @savaslab RT @NCICancerStats: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: https://t.co/IlNVjtpQ3z #LCSM https://t.co/m1DtoSh8DP |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell But blocking this protection from self-immune-attack also can allow unintended autoimmune attack on healthy organs, which are all the side effects of checkpoint inhibitors: inflammation of <insert organ name> #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: It's important for patients to know if they are receiving immunotherapy or chemotherapy--side effects are treated differently #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: T1: T1: Magic! No, kidding! Immune checkpoints help prevent auto(self)immunity, but Cancer takes advantage of that to escape the immune system since it is technically “you”, no matter how abnormal #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: T1 cont: T1 cont: so by blocking these checkpoints (like CTLA-4 and PD-1/PDL1) we stop that from happening and the immune system can attack #lcsm |
| Brendon Stiles @BrendonStilesMD @sjwhitlock Your beautiful thyroid! Blame @n8pennell #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: But blocking this protection from self-immune-attack also can allow unintended autoimmune attack on healthy organs, which are all the side effects of checkpoint inhibitors: inflammation of <insert organ name> #lcsm |
| Dr. David Tom Cooke @DavidCookeMD And the #lungcancer says: "Papers! Papers?! We don't need no stinking papers!" #LCSM #immunotherapy |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Side effects are generally less than with chemotherapy, but are unique and include many “itis” problems. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti RT @VamsiVelchev: W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat |
| Dr. David Tom Cooke @DavidCookeMD RT @TimAllenMDJD: #lcsm https://t.co/KdUH8CEP5D |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: "IO" is a shorthand way to say "immunotherapy" @KathleenSkambis @VamsiVelchev @n8pennell #lcsm |
| Denise Cutlip @dennycee T1: still learning about long term side effects. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #immunotherapy #lcsm https://t.co/xjlNhhTU9L |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @JackWestMD: @DavidCookeMD Good analogy: @DavidCookeMD Good analogy: Here a tumor w/high PD-L1 is like a thief who has fake credentials that make immune system more complacent about presuming he should be left alone. Removing credentials & forcing closer look by guard -> better recognition of who belongs & who doesn't. #LCSM |
| Brendon Stiles @BrendonStilesMD @VamsiVelchev Great point and topic for research! #lcsm |
| Peggy Dennis @peggyddennis RT @BrendonStilesMD: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm |
| Janet Freeman-Daily @JFreemanDaily @dennycee The trick with immunotherapy is to rev up the immune system enough that it sees the cancer without attacking normal tissue #lcsm |
| H. Jack West, MD @JackWestMD @KathleenSkambis @VamsiVelchev @n8pennell IO stands for "immuno-oncology", basically just immunotherapy in the setting of oncology. The most common abbreviation for a long word/concept. #LCSM |
| Brendon Stiles @BrendonStilesMD @DavidCookeMD I have had some patients with profound pneumonitis. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T1: T1: It's important for patients to know if they are receiving immunotherapy or chemotherapy--side effects are treated differently #lcsm |
| Faces of Lung Cancer @LungCancerFaces @diianeee Hi Diane! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @dennycee The trick with immunotherapy is to rev up the immune system enough that it sees the cancer without attacking normal tissue #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell @sjwhitlock This is why I annoy the oncologists.... #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: Has anyone in the #LCSM community experienced #Immunotherapy side affects, and if so what were/ are they? #LCSM https://t.co/PxzjRlkq0k |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD Chemotherapy- Radiation- Vaccines- Epigenetic therapy can turn the 💡 in the tumor ON #LCSM |
| Janet Freeman-Daily @JFreemanDaily @diianeee Welcome! #lcsm |
| Denise Cutlip @dennycee @JFreemanDaily @dennycee understood! #lcsm |
| Dr. David Tom Cooke @DavidCookeMD That's where the "Itis" side affects come in. Also, people with autoimmune disorders should mostly stay away from #immunotherapy #LCSM https://t.co/DXWl44KAUg |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Some have also used ICI for immune checkpoint inhibitors #LCSM https://t.co/i5e5D615iq |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: @KathleenSkambis @VamsiVelchev @n8pennell IO stands for "immuno-oncology", basically just immunotherapy in the setting of oncology. The most common abbreviation for a long word/concept. #LCSM |
| Brendon Stiles @BrendonStilesMD @DrewMoghanaki in the house. I'm feeling a little abscopal. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: @n8pennell @sjwhitlock This is why I annoy the oncologists.... #lcsm |
| #LCSM Chat @lcsmchat RT @rants_by_egg: #lcsm fatigue is my only side effect, easy to push through...but fatigue could be due to age, confounding variable |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @DavidCookeMD I have had some patients with profound pneumonitis. #lcsm |
| Michele @rants_by_egg T1 fatigue is my only side effect, could be due to age, confounding effect! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @DavidCookeMD Good analogy: @DavidCookeMD Good analogy: Here a tumor w/high PD-L1 is like a thief who has fake credentials that make immune system more complacent about presuming he should be left alone. Removing credentials & forcing closer look by guard -> better recognition of who belongs & who doesn't. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @rants_by_egg: T1 fatigue is my only side effect, could be due to age, confounding effect! #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: #lcsm https://t.co/KdUH8CEP5D |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DavidCookeMD: That's where the "Itis" side affects come in. Also, people with autoimmune disorders should mostly stay away from #immunotherapy #LCSM https://t.co/DXWl44KAUg |
| H. Jack West, MD @JackWestMD @n8pennell or CPI for checkpoint inhibitor #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @BrendonStilesMD Tumors need to have 💡 on to have immune response i.e respond to checkpoint inhibitors unfortunately most don’t have the 💡 on and need more to make them response to immunotherapy #LCSM |
| #LCSM Chat @lcsmchat RT @dennycee: T1: T1: I’ve had friends develop arthritis, thyroid and pancreas issues shortly after starting pembrolizumab. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: It's important for patients to know if they are receiving immunotherapy or chemotherapy--side effects are treated differently #lcsm |
| Dr. David Tom Cooke @DavidCookeMD Quick, fetch me my dictionary. #LCSM https://t.co/WLGOPzzDey |
 | Drew Moghanaki @DrewMoghanaki Hi team! I’m a Radiation Oncologist who takes care of Veterans with cancer at the Richmond VAMC. Glad to join. #lcsm |
| Brendon Stiles @BrendonStilesMD Tough questions coming up. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. As these drugs are more commonly used, doctors need to be more aware of side effects. https://t.co/UcSfnXz1qC #lcsm |
| #LCSM Chat @lcsmchat RT @dennycee: T1: T1: still learning about long term side effects. #lcsm |
| Denise Cutlip @dennycee @DrewMoghanaki welcome! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @dennycee The trick with immunotherapy is to rev up the immune system enough that it sees the cancer without attacking normal tissue #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @KathleenSkambis @VamsiVelchev @n8pennell IO stands for "immuno-oncology", basically just immunotherapy in the setting of oncology. The most common abbreviation for a long word/concept. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @DavidCookeMD I have had some patients with profound pneumonitis. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @BrendonStilesMD Chemotherapy- Radiation- Vaccines- Epigenetic therapy can turn the 💡 in the tumor ON #LCSM |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: That's where the "Itis" side affects come in. Also, people with autoimmune disorders should mostly stay away from #immunotherapy #LCSM https://t.co/DXWl44KAUg |
| #LCSM Chat @lcsmchat RT @n8pennell: Some have also used ICI for immune checkpoint inhibitors #LCSM https://t.co/i5e5D615iq |
| Brendon Stiles @BrendonStilesMD @sjwhitlock @n8pennell He is forgiven. #lcsm |
| #LCSM Chat @lcsmchat RT @rants_by_egg: T1 fatigue is my only side effect, could be due to age, confounding effect! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @n8pennell or CPI for checkpoint inhibitor #LCSM |
| #LCSM Chat @lcsmchat RT @DrewMoghanaki: Hi team! I’m a Radiation Oncologist who takes care of Veterans with cancer at the Richmond VAMC. Glad to join. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Important to remember…only 15-30% will benefit. #lcsm |
 | Lung Cancer Sux @LungCancerSux #lcsm https://t.co/qFHIG4FCGl |
| Krishna Soujanya Gunturu MD @kgunturuMD T1 We are seeing more and more side effects including cardiotoxicty as more people are being treated and followed longer #LCSM https://t.co/ZFMSoJ9YfN |
| Brendon Stiles @BrendonStilesMD T2. But remarkably, almost ALL stage IV lung cancer patients should now be considered for immunotherapy! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. Important to remember…only 15-30% will benefit. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Immunotherapy has moved into the frontline setting for patients with metastatic cancer. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Actually most autoimmune disorders still pretty safe to use ICI/CPIs, low % need to stop drug. Especially if relatively mild or dormant #LCSM https://t.co/cCILc91yKk |
| Janet Freeman-Daily @JFreemanDaily T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
| Dr. David Tom Cooke @DavidCookeMD A2 Better than Zero. #Immunotherapy #LCSM https://t.co/nQLnWq6TIK |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #hope #lcsm https://t.co/hgtBtbC3iP |
| #LCSM Chat @lcsmchat T2: Which patients should be considered for immunotherapy and are the drugs different? #lcsm https://t.co/KOyPz6Viyt |
| Dr. David Tom Cooke @DavidCookeMD RT @JFreemanDaily: T1: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
 | Dee Sparacio @womenofteal RT @JFreemanDaily: @btrfly12 @itsthebunk @stales @womenofteal @TheLizArmy @CBlotner_ @MyelomaTeacher #LCSM Chat created a list of vetted online #lungcancer resources here, plus maintains a list of #lungcancer bloggers. Don’t have a list of patient groups though—hmmm... https://t.co/gn7LxTiJXx |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Important to remember…only 15-30% will benefit. #lcsm |
 | Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @JFreemanDaily @n8pennell Good evening! Sorry to be joining late, I had to pick up kids from rowing team event. Hi folks! #lcsm |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T1 We are seeing more and more side effects including cardiotoxicty as more people are being treated and followed longer #LCSM https://t.co/ZFMSoJ9YfN |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. But remarkably, almost ALL stage IV lung cancer patients should now be considered for immunotherapy! #lcsm |
| Denise Cutlip @dennycee T2: learning that tumor burden improved outcomes excited this former smoker. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Immunotherapy has moved into the frontline setting for patients with metastatic cancer. #lcsm |
 | Lecia Sequist, MD, MPH @LeciaSequist Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO agents are fundamentally different than any others. Seems like good clin trial designs and a bit of luck are the differences b/w drugs |
| #LCSM Chat @lcsmchat RT @n8pennell: Actually most autoimmune disorders still pretty safe to use ICI/CPIs, low % need to stop drug. Especially if relatively mild or dormant #LCSM https://t.co/cCILc91yKk |
| Vamsi Velcheti, MD @VamsiVelcheti @RedGia unfortunately some of the endocrine side effects of IO are irreversible but easy to treat.. key is early detection and close monitoring #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
| Brendon Stiles @BrendonStilesMD T2. For patients with PD-L1 expression >50%, Keytruda monotherapy (@merck) is indicated for both adeno and squamous #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #lcsm Must leave because #PatientsFirst It was a privilege to participate. |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: A2 Better than Zero. #Immunotherapy #LCSM https://t.co/nQLnWq6TIK |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: #hope #lcsm https://t.co/hgtBtbC3iP |
| Dr. David Tom Cooke @DavidCookeMD A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM |
| #LCSM Chat @lcsmchat RT @dennycee: T2: T2: learning that tumor burden improved outcomes excited this former smoker. #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO agents are fundamentally different than any others. Seems like good clin trial designs and a bit of luck are the differences b/w drugs |
| Brendon Stiles @BrendonStilesMD T2. Keytruda more than doubled overall survival compared to chemo! KEYNOTE-024 #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @RedGia unfortunately some of the endocrine side effects of IO are irreversible but easy to treat.. key is early detection and close monitoring #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @n8pennell: Actually most autoimmune disorders still pretty safe to use ICI/CPIs, low % need to stop drug. Especially if relatively mild or dormant #LCSM https://t.co/cCILc91yKk |
| Janet Freeman-Daily @JFreemanDaily Hi @leciasequist! Good to see you. #lcsm |
| Flemming Rasmussen @fgrazz RT @BrendonStilesMD: T2. Important to remember…only 15-30% will benefit. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. For patients with PD-L1 expression >50%, Keytruda monotherapy (@merck) is indicated for both adeno and squamous #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM |
 | Liz Highleyman @LizCancerHealth @BrendonStilesMD But docs & nurses have rapidly gotten better at promptly recognizing & managing them #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Keytruda can also be used with chemotherapy for patients with PD-L1 expression less than 50% #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in very very ill patients who might benefit from hospice for example #lcsm |
| Brendon Stiles @BrendonStilesMD @LeciaSequist @MGHCancerCenter Thanks for joining! #lcsm |
| Sara Whitlock @sjwhitlock T2:But is it true that people with a specific driver are less likely to benefit? #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @JFreemanDaily @n8pennell Concept of the abscopal effect is that radiation treatment to one part of the body can contribute to a tumor response somewhere else in the body. Ab-scopal = out of the 'scope' of the radiation field #lcsm #radonc |
| Janet Freeman-Daily @JFreemanDaily T2: Most #lungcancer patients whose cancers have driving mutations (EGFR, ALK, ROS1, BRAF, etc.) should NOT have IO as first treatment #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Opdivo (@bmsnews – Checkmate-017) and Tecentriq (@genentech - OAK) can be used if you have progressed after chemotherapy. So can Keytruda. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @sjwhitlock No you don't! Just remember to add #lcsm to your tweets. |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @JFreemanDaily: T1: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
| Brendon Stiles @BrendonStilesMD @sjwhitlock Hey! That is next question! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @n8pennell: T2: T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in very very ill patients who might benefit from hospice for example #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T2: Also focus of most trials today to increase the % of pts who benefit, and so far lost of promise! #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Opdivo and Keytruda are PD1 inhibitors, while Tecentriq and Imfinzi are PD-L1 inhibitors. #lcsm |
| H. Jack West, MD @JackWestMD T2) Most pts are candidates for IO, mostly just Q of when. Not good for pts w/major auto-immune dzs. Otherwise, evidence now supports giving alone as 1st Rx if PD-L1 high or poss low range, or w/chemo for most others except pts w/driver mut'n like EGFR, ALK, etc.-> later. #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @sjwhitlock Hi @sjwhitlock! This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story. #LCSM |
| #LCSM Chat @lcsmchat #lcsm https://t.co/Y98uf36Cx8 |
| Brendon Stiles @BrendonStilesMD T2. It is still not clear which patients respond best. PD-L1 expression is commonly used but is not perfect for predicting response. #lcsm |
| Denise Cutlip @dennycee T2: some patients fear mentioning side effects- fear of losing IO treatment. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @LeciaSequist @MGHCancerCenter Good evening Lecia! #lcsm |
 | NoRmiΞ5 @NoRmiE55 @DavidCookeMD After my dad’s first keytruda treatment a few weeks ago he had been bed ridden - says it feels like his neck snapped and can’t sit up for long periods of time #LCSM |
| Kathleen Skambis @KathleenSkambis RT @JFreemanDaily: T1: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @DrewMoghanaki Hi Drew! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Keytruda more than doubled overall survival compared to chemo! KEYNOTE-024 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @sjwhitlock Hi @sjwhitlock! This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story. #LCSM |
| #LCSM Chat @lcsmchat RT @LizCancerHealth: @BrendonStilesMD But docs & nurses have rapidly gotten better at promptly recognizing & managing them #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @dennycee: T2: T2: some patients fear mentioning side effects- fear of losing IO treatment. #lcsm |
| Liz Highleyman @LizCancerHealth @LeciaSequist @MGHCancerCenter The CTLA-4 & PD-1/PD-L1 classes differ from each other, but within a class it seems like not so much. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. “Tumor mutation burden” may also predict response – how many total mutations does your tumor have (requires special sequencing). #lcsm |
| Kathleen Skambis @KathleenSkambis RT @TimAllenMDJD: #hope #lcsm https://t.co/hgtBtbC3iP |
| #LCSM Chat @lcsmchat RT @n8pennell: T2: T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in very very ill patients who might benefit from hospice for example #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Keytruda can also be used with chemotherapy for patients with PD-L1 expression less than 50% #lcsm |
| #LCSM Chat @lcsmchat RT @sjwhitlock: T2:But is it true that people with a specific driver are less likely to benefit? #LCSM |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @JFreemanDaily @n8pennell Concept of the abscopal effect is that radiation treatment to one part of the body can contribute to a tumor response somewhere else in the body. Ab-scopal = out of the 'scope' of the radiation field #lcsm #radonc |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: Most #lungcancer patients whose cancers have driving mutations (EGFR, ALK, ROS1, BRAF, etc.) should NOT have IO as first treatment #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @DavidCookeMD neoadjuvant trials are critical not only to improve long term outcomes but great opportunity for understanding MOA of the IO drugs and biomarker discovery #LCSM @BrendonStilesMD |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Opdivo (@bmsnews – Checkmate-017) and Tecentriq (@genentech - OAK) can be used if you have progressed after chemotherapy. So can Keytruda. #lcsm |
| Krishna Soujanya Gunturu MD @kgunturuMD T2. There are different FDA approved immunotherapy agents. Like pembrolozimab is approved if PD expression is above 50% in first line setting. Durvalumab is approved after chemo radiation for stage III who can’t undergo surgery. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: T2: T2: Also focus of most trials today to increase the % of pts who benefit, and so far lost of promise! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Opdivo and Keytruda are PD1 inhibitors, while Tecentriq and Imfinzi are PD-L1 inhibitors. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: T2) Most pts are candidates for IO, mostly just Q of when. Not good for pts w/major auto-immune dzs. Otherwise, evidence now supports giving alone as 1st Rx if PD-L1 high or poss low range, or w/chemo for most others except pts w/driver mut'n like EGFR, ALK, etc.-> later. #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P |
| Mark Lewis @marklewismd See also the great @Bob_Wachter article in the @nytimes on precisely this issue: https://t.co/DtKYanrDHs #lcsm https://t.co/tMnbwI5OA4 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. It is still not clear which patients respond best. PD-L1 expression is commonly used but is not perfect for predicting response. #lcsm |
| #LCSM Chat @lcsmchat RT @dennycee: T2: T2: some patients fear mentioning side effects- fear of losing IO treatment. #lcsm |
| #LCSM Chat @lcsmchat RT @NoRmiE55: @DavidCookeMD After my dad’s first keytruda treatment a few weeks ago he had been bed ridden - says it feels like his neck snapped and can’t sit up for long periods of time #LCSM |
| Peggy Dennis @peggyddennis @BrendonStilesMD Mine is 4....was initially told that immuno might not be a great option. Changing tunes? #lcsm |
| #LCSM Chat @lcsmchat RT @LizCancerHealth: @LeciaSequist @MGHCancerCenter The CTLA-4 & PD-1/PD-L1 classes differ from each other, but within a class it seems like not so much. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. “Tumor mutation burden” may also predict response – how many total mutations does your tumor have (requires special sequencing). #lcsm |
| Brendon Stiles @BrendonStilesMD @VamsiVelchev @DavidCookeMD Will get to this in a bit- totally agree! #lcsm |
| Kathleen Skambis @KathleenSkambis RT @LeciaSequist: Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO agents are fundamentally different than any others. Seems like good clin trial designs and a bit of luck are the differences b/w drugs |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @DavidCookeMD neoadjuvant trials are critical not only to improve long term outcomes but great opportunity for understanding MOA of the IO drugs and biomarker discovery #LCSM @BrendonStilesMD |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T2. There are different FDA approved immunotherapy agents. Like pembrolozimab is approved if PD expression is above 50% in first line setting. Durvalumab is approved after chemo radiation for stage III who can’t undergo surgery. #lcsm |
| Denise Cutlip @dennycee So much great info already tonight! #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist Big logistical hurdle is that there is not yet an agreed upon standard for measuring TMB. #LCSM https://t.co/5L9qh2LJsJ |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P |
| #LCSM Chat @lcsmchat RT @marklewismd: See also the great @Bob_Wachter article in the @nytimes on precisely this issue: See also the great @Bob_Wachter article in the @nytimes on precisely this issue: https://t.co/DtKYanrDHs #lcsm https://t.co/tMnbwI5OA4 |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P |
| H. Jack West, MD @JackWestMD T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T1: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
| Dee Sparacio @womenofteal RT @JackWestMD: T2) Most pts are candidates for IO, mostly just Q of when. Not good for pts w/major auto-immune dzs. Otherwise, evidence now supports giving alone as 1st Rx if PD-L1 high or poss low range, or w/chemo for most others except pts w/driver mut'n like EGFR, ALK, etc.-> later. #LCSM |
| colleen ziegler @ZieglerColleen RT @BrendonStilesMD: T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P |
| Dr. David Tom Cooke @DavidCookeMD RT @dennycee: So much great info already tonight! #lcsm |
| Kathleen Skambis @KathleenSkambis RT @DavidCookeMD: A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM |
| Brendon Stiles @BrendonStilesMD @LeciaSequist Will be challenging to implement clinically. #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist Yes! I should clarify. I meant differences between PD1/PDL1 drugs ! thanks #LCSM https://t.co/wM7StivQ7G |
| Krishna Soujanya Gunturu MD @kgunturuMD T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co/TtMs26WfCs |
| Janet Freeman-Daily @JFreemanDaily per @LeciaSequist: This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story. (in response to @sjwhitlock "Is it true that people with a specific driver are less likely to benefit?") #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @VamsiVelchev: @DavidCookeMD neoadjuvant trials are critical not only to improve long term outcomes but great opportunity for understanding MOA of the IO drugs and biomarker discovery #LCSM @BrendonStilesMD |
 | Mark B In SD @MomsOopsBaby RT @BrendonStilesMD: T2. It is still not clear which patients respond best. PD-L1 expression is commonly used but is not perfect for predicting response. #lcsm |
| Brendon Stiles @BrendonStilesMD T3 coming up. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @marklewismd @JFreemanDaily @n8pennell No. Although arguably Dr. Abscopal's like Elijah at Passover. You have to leave the room, open the door to let in an invisible man. When you come back, the wine is gone #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: Big logistical hurdle is that there is not yet an agreed upon standard for measuring TMB. #LCSM https://t.co/5L9qh2LJsJ |
| #LCSM Chat @lcsmchat RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| Brendon Stiles @BrendonStilesMD T3: Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @sjwhitlock T2: Still a lot of work needed to improve IO options for pts w/ driver mutations- Some early suggestions that chemo-bevacizumab-IO combinations may be beneficial- need to be confirmed in larger trials #LCSM |
| Brendon Stiles @BrendonStilesMD T3. This is a challenging question. Because they have other good drugs available, these patients have been excluded from many trials. #lcsm |
| Dee Sparacio @womenofteal RT @subatomicdoc: @JFreemanDaily @n8pennell Concept of the abscopal effect is that radiation treatment to one part of the body can contribute to a tumor response somewhere else in the body. Ab-scopal = out of the 'scope' of the radiation field #lcsm #radonc |
| #LCSM Chat @lcsmchat RT @LeciaSequist: Yes! I should clarify. I meant differences between PD1/PDL1 drugs ! thanks #LCSM https://t.co/wM7StivQ7G |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co/TtMs26WfCs |
| Michele @rants_by_egg T2 OpD wasn't supposed to work for me. Was part of initial prep to receive t-cells. Surprise! T-cells back in deep freeze for 2nd line of defense. Staying w/ OpD. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: per @LeciaSequist: per @LeciaSequist: This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story. (in response to @sjwhitlock "Is it true that people with a specific driver are less likely to benefit?") #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Evidence suggests that they may not respond as well to immunotherapy. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: T3: T3: Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @marklewismd @JFreemanDaily @n8pennell No. Although arguably Dr. Abscopal's like Elijah at Passover. You have to leave the room, open the door to let in an invisible man. When you come back, the wine is gone #lcsm |
 | MiVQ @MichRadioactiva RT @JAMAOnc: What is the association between ERBB family mutations and outcomes of patients with lung squamous cell #carcinoma who received treatment with #afatinib dimaleate or #erlotinib hydrochloride? Find out https://t.co/h3MePdR1Sl #LCSM https://t.co/rWeiBn84ov |
| Paula Ashton @paulalv RT @krishna_gunturu: T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co/TtMs26WfCs |
| Brendon Stiles @BrendonStilesMD T3. EGFR/ALK+ patients had no benefit in CheckMate 057, KEYNOTE-10, OAK, or PACIFIC trials. #lcsm |
| Diane 🧚🏻♀️ @diianeee T3: I talked with my onc today about IO as an option for my egfr LC and she seemed to hinknit is promising sooner than later. #lcsm |
| Peggy Dennis @peggyddennis T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM |
| Cafer BAŞ @brtmnbs @krishna_gunturu T1: Are the practical dose of pembro and the dose in the clinical trial (2mg/kg I suppose) different? May the severe or long term side effects be because of this? #lcsm |
| #LCSM Chat @lcsmchat @subatomicdoc @marklewismd @JFreemanDaily @n8pennell My daughter, the Cantor, will appreciate this. -Deana #lcsm |
| Dee Sparacio @womenofteal @subatomicdoc @JFreemanDaily @n8pennell I had never heard that term before. Thanks for explaining. Could you see that in endometrial cancer ? #lcsm #radonc |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @marklewismd @JFreemanDaily @n8pennell Both fit with abscopal effect. Great stories, but still lacking robust evidence. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Fortunately, there are lots of ongoing trials! https://t.co/JY4yyLgBbt #lcsm |
| Liz Highleyman @LizCancerHealth @JackWestMD Is there a reason checkpoint inhibitors don't work well for 1st line treatment -- or is the issue that targeted therapies work better at that point so try them first? #lcsm |
| Janet Freeman-Daily @JFreemanDaily Yes, but for most patients with activating mutations, immunotherapy should wait until targeted therapy and then chemo have been tried. #LCSM https://t.co/Ilz4ivqFvm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3: T3: Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. It may be that immunotherapy may work in these patients in combination with other therapies – radiation, antiangiogenic, etc. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD patients with driver mutations especially EGFR, ALK, ROS should not be treated with IO upfront... IO only an option after or with chemotherapy #LCSM |
| Brendon Stiles @BrendonStilesMD How about that shout out to #radonc???? #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhausting possible targeted options is the best lead we have currently though #LCSM https://t.co/6sAkFTfisX |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @sjwhitlock T2: @sjwhitlock T2: Still a lot of work needed to improve IO options for pts w/ driver mutations- Some early suggestions that chemo-bevacizumab-IO combinations may be beneficial- need to be confirmed in larger trials #LCSM |
| H. Jack West, MD @JackWestMD T3) As noted in prior tweet, IO agents should NOT be initial Rx for pts w/driver mutns. Most evidence shows marginal benefit at best, at least given as single agents -> wouldn't say never, but low priority. Some data now supports giving w/chemo (+/- Avastin) may be bettter. #LCSM |
 | Saman Maleki, PhD @SMImmunology @sjwhitlock For anti-PD1 drugs to work, tumor-recognizing T cells need to already exist. Pts with driver mutations tend to have less of those T cells in their tumors. That's why single anti-PD1 drugs don't work as well in these pts #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. This is a challenging question. Because they have other good drugs available, these patients have been excluded from many trials. #lcsm |
| #LCSM Chat @lcsmchat RT @rants_by_egg: T2 OpD wasn't supposed to work for me. Was part of initial prep to receive t-cells. Surprise! T-cells back in deep freeze for 2nd line of defense. Staying w/ OpD. #lcsm |
| Janet Freeman-Daily @JFreemanDaily This deserves an #LCSM, Nate https://t.co/FGQr2bkbMJ |
| Brendon Stiles @BrendonStilesMD Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Evidence suggests that they may not respond as well to immunotherapy. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. EGFR/ALK+ patients had no benefit in CheckMate 057, KEYNOTE-10, OAK, or PACIFIC trials. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| #LCSM Chat @lcsmchat RT @diianeee: T3: T3: I talked with my onc today about IO as an option for my egfr LC and she seemed to hinknit is promising sooner than later. #lcsm |
| #LCSM Chat @lcsmchat RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM |
| #LCSM Chat @lcsmchat RT @brtmnbs: @krishna_gunturu T1: @krishna_gunturu T1: Are the practical dose of pembro and the dose in the clinical trial (2mg/kg I suppose) different? May the severe or long term side effects be because of this? #lcsm |
| Dee Sparacio @womenofteal Just dropping in since I am usually not home on Thurs nights. Dee #ovca survivor and #gyncsm moderator #lcsm |
| colleen ziegler @ZieglerColleen RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| Vamsi Velcheti, MD @VamsiVelcheti @RedGia with these drugs now more widely used.. oncologists are getting more familiar with these unique side effects.. but still more education needed #LCSM |
| #LCSM Chat @lcsmchat RT @womenofteal: @subatomicdoc @JFreemanDaily @n8pennell I had never heard that term before. Thanks for explaining. Could you see that in endometrial cancer ? #lcsm #radonc |
| Denise Cutlip @dennycee Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM |
| Liz Highleyman @LizCancerHealth RT @LeciaSequist: I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhausting possible targeted options is the best lead we have currently though #LCSM https://t.co/6sAkFTfisX |
| Brendon Stiles @BrendonStilesMD @sjwhitlock This is always a challenge. People don't opt for trials until disease is too far gone. We as doctors need to do better managing/explaining. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @womenofteal @JFreemanDaily @n8pennell Potentially. Currently, the hope is that radiation can be used to induce cancer cells to express antigens (or molecular 'red flags') that make cancer cells more identifiable by the immune system, and hypothetically making immunotherapy more effective. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Fortunately, there are lots of ongoing trials! https://t.co/JY4yyLgBbt #lcsm |
| #LCSM Chat @lcsmchat RT @LizCancerHealth: @JackWestMD Is there a reason checkpoint inhibitors don't work well for 1st line treatment -- or is the issue that targeted therapies work better at that point so try them first? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Yes, but for most patients with activating mutations, immunotherapy should wait until targeted therapy and then chemo have been tried. #LCSM https://t.co/Ilz4ivqFvm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. It may be that immunotherapy may work in these patients in combination with other therapies – radiation, antiangiogenic, etc. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @dennycee: Excellent question RT @peggyddennis: Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @BrendonStilesMD patients with driver mutations especially EGFR, ALK, ROS should not be treated with IO upfront... IO only an option after or with chemotherapy #LCSM |
| H. Jack West, MD @JackWestMD @LizCancerHealth This is only for pts w/EGFR mut'n, not generally. For patients who don't have a driver mutation like EGFR, ALK, etc., latest evidence supports single agent pembrolizumab (Keytruda) for some (esp those w/high PD-L1, +/- those w/lower), or w/chemo combination for most others. #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| Denise Cutlip @dennycee @womenofteal welcome #lcsm |
| Dee Sparacio @womenofteal @JFreemanDaily LOL #lcsm |
| Kathleen Skambis @KathleenSkambis RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhausting possible targeted options is the best lead we have currently though #LCSM https://t.co/6sAkFTfisX |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @JFreemanDaily: This deserves an #LCSM, Nate https://t.co/FGQr2bkbMJ |
| #LCSM Chat @lcsmchat RT @JackWestMD: T3) As noted in prior tweet, IO agents should NOT be initial Rx for pts w/driver mutns. Most evidence shows marginal benefit at best, at least given as single agents -> wouldn't say never, but low priority. Some data now supports giving w/chemo (+/- Avastin) may be bettter. #LCSM |
| #LCSM Chat @lcsmchat RT @SMImmunology: @sjwhitlock For anti-PD1 drugs to work, tumor-recognizing T cells need to already exist. Pts with driver mutations tend to have less of those T cells in their tumors. That's why single anti-PD1 drugs don't work as well in these pts #LCSM |
| Saman Maleki, PhD @SMImmunology Hi #LCSM. I am a tumor immunologist from @SchulichMedDent happy to join the chat and answer immunology questions about #immunotherapy |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: This deserves an #LCSM, Nate https://t.co/FGQr2bkbMJ |
| Brendon Stiles @BrendonStilesMD T3. Someone tell us about abscopal and antiangiogenic combo! #lcsm |
| Kathleen Skambis @KathleenSkambis RT @krishna_gunturu: T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co/TtMs26WfCs |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @RedGia with these drugs now more widely used.. oncologists are getting more familiar with these unique side effects.. but still more education needed #LCSM |
| Dee Sparacio @womenofteal RT @SMImmunology: @sjwhitlock For anti-PD1 drugs to work, tumor-recognizing T cells need to already exist. Pts with driver mutations tend to have less of those T cells in their tumors. That's why single anti-PD1 drugs don't work as well in these pts #LCSM |
| #LCSM Chat @lcsmchat RT @dennycee: Excellent question RT @peggyddennis: Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM |
| Brendon Stiles @BrendonStilesMD @SMImmunology @SchulichMedDent Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @sjwhitlock This is always a challenge. People don't opt for trials until disease is too far gone. We as doctors need to do better managing/explaining. #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @womenofteal @JFreemanDaily @n8pennell Potentially. Currently, the hope is that radiation can be used to induce cancer cells to express antigens (or molecular 'red flags') that make cancer cells more identifiable by the immune system, and hypothetically making immunotherapy more effective. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @LizCancerHealth This is only for pts w/EGFR mut'n, not generally. For patients who don't have a driver mutation like EGFR, ALK, etc., latest evidence supports single agent pembrolizumab (Keytruda) for some (esp those w/high PD-L1, +/- those w/lower), or w/chemo combination for most others. #LCSM |
| Paula Ashton @paulalv RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| Cafer BAŞ @brtmnbs @JackWestMD What about pts with mutations but high PD-L1 as well? #lcsm |
| #LCSM Chat @lcsmchat RT @SMImmunology: Hi #LCSM. I am a tumor immunologist from @SchulichMedDent happy to join the chat and answer immunology questions about #immunotherapy |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Someone tell us about abscopal and antiangiogenic combo! #lcsm |
| H. Jack West, MD @JackWestMD RT @JFreemanDaily: Yes, but for most patients with activating mutations, immunotherapy should wait until targeted therapy and then chemo have been tried. #LCSM https://t.co/Ilz4ivqFvm |
| Brendon Stiles @BrendonStilesMD T3. Had a patient w/ BRAF mutation ask about immunotherapy. Seems like some data in melanoma. Any thoughts for lung? #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @brtmnbs @JackWestMD This was specifically tested in EGFR mutant patients and they don’t respond to single agent CPIs even with high PDL1 #lcsm |
| #LCSM Chat @lcsmchat RT @brtmnbs: @JackWestMD What about pts with mutations but high PD-L1 as well? #lcsm |
 | Anita Figueras @scifiknitter T3 Anita chiming in. EGFR patients are getting the Pembro & chemo triplet as treatment after TKIs are exhausted. #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: @brtmnbs @JackWestMD This was specifically tested in EGFR mutant patients and they don’t respond to single agent CPIs even with high PDL1 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Had a patient w/ BRAF mutation ask about immunotherapy. Seems like some data in melanoma. Any thoughts for lung? #lcsm |
| Krishna Soujanya Gunturu MD @kgunturuMD T1 not 100% sure if the dose is the cause for toxicity as nivolumab dose was also different than initial trials. Mechanism is activating the immune system and taking the breaks away. We don’t have any evidence to think that dose is correlated with toxicity unlike chemo. #LCSM https://t.co/COwVeH7NSO |
| Kathleen Skambis @KathleenSkambis RT @LeciaSequist: I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhausting possible targeted options is the best lead we have currently though #LCSM https://t.co/6sAkFTfisX |
| Denise Cutlip @dennycee @scifiknitter Hi Anita! #lcsm |
| Dee Sparacio @womenofteal @subatomicdoc @JFreemanDaily @n8pennell Interesting. #lcsm |
 | Alex Spira, M.D. @AlexSpiraMDPhD RT @LeciaSequist: Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO agents are fundamentally different than any others. Seems like good clin trial designs and a bit of luck are the differences b/w drugs |
 | Tong Yin @TongYin_MD RT @ivybelkins: As a stage IV lung cancer patient, I’ve been on targeted therapy for almost 5 years and it’s certainly been a game-changer for me. I’ve been able to live a normal, active life while seeing my kids grow into teenagers and celebrating many milestones with my family! #lcsm https://t.co/HGVycEivXy |
| Mark Lewis @marklewismd A3. GI here. The lesson from brat-mutant colon cancer has been that you actually drive resistance in CRC by only using an inhibitor like vemurafenib. Have to also block EGFR e.g. S1404 (breaking my own rules of cross-trial and cross-tumor comparison!) #lcsm https://t.co/x7JD6P3B3K |
| Brendon Stiles @BrendonStilesMD @brtmnbs @JackWestMD I think data shows, IO still no good. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @BrendonStilesMD BRAF patient seem to be the one mutant lung cancer population that has a similar response rate to non-mutant Lung Cancer, possibly because more common in smokers so more mutations #lcsm |
 | Francie Pucharich @fpucharich #LCSM |
| Janet Freeman-Daily @JFreemanDaily We don't know. #lungcancer patients who have activating mutations usually don't respond to first-line immunotherapy even if they test high for PD-L1. TMB is too new for us to have that data. #LCSM https://t.co/Ptu1zIwKUZ |
| Peggy Dennis @peggyddennis @BrendonStilesMD Can't speak to abscopal positively but Docetaxel/Ramucirumab (anti-angiogenic) has kept me stable for a year now. #lcsm |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T1 not 100% sure if the dose is the cause for toxicity as nivolumab dose was also different than initial trials. Mechanism is activating the immune system and taking the breaks away. We don’t have any evidence to think that dose is correlated with toxicity unlike chemo. #LCSM https://t.co/COwVeH7NSO |
| Kathleen Skambis @KathleenSkambis RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| #LCSM Chat @lcsmchat RT @marklewismd: A3. GI here. The lesson from brat-mutant colon cancer has been that you actually drive resistance in CRC by only using an inhibitor like vemurafenib. Have to also block EGFR e.g. S1404 (breaking my own rules of cross-trial and cross-tumor comparison!) #lcsm https://t.co/x7JD6P3B3K |
| Cafer BAŞ @brtmnbs @BrendonStilesMD T3 : combination therapies ie parp inhibitors and IO increases the success in ovarian cancers #lcsm |
| Brendon Stiles @BrendonStilesMD @marklewismd You know what they say about rules. And cancer. Break 'em. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: @BrendonStilesMD BRAF patient seem to be the one mutant lung cancer population that has a similar response rate to non-mutant Lung Cancer, possibly because more common in smokers so more mutations #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Gotta go, was fun! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @n8pennell Thanks for joining us! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We don't know. #lungcancer patients who have activating mutations usually don't respond to first-line immunotherapy even if they test high for PD-L1. TMB is too new for us to have that data. #LCSM https://t.co/Ptu1zIwKUZ |
| Brendon Stiles @BrendonStilesMD @n8pennell Thanks for joining. You are the man. #lcsm |
| #LCSM Chat @lcsmchat RT @brtmnbs: @BrendonStilesMD T3 : @BrendonStilesMD T3 : combination therapies ie parp inhibitors and IO increases the success in ovarian cancers #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @marklewismd You know what they say about rules. And cancer. Break 'em. #lcsm |
| Alex Spira, M.D. @AlexSpiraMDPhD RT @ivybelkins: As a stage IV lung cancer patient, I’ve been on targeted therapy for almost 5 years and it’s certainly been a game-changer for me. I’ve been able to live a normal, active life while seeing my kids grow into teenagers and celebrating many milestones with my family! #lcsm https://t.co/HGVycEivXy |
| Brendon Stiles @BrendonStilesMD Fun stuff coming up. Earlier stage! #lcsm |
| Janet Freeman-Daily @JFreemanDaily It's been a while since #LCSM Chat was so busy that I couldn't keep up! Seems immunotherapy brings everyone out of the woodwork. |
| Brendon Stiles @BrendonStilesMD T4. Is there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @peggyddennis @BrendonStilesMD That's great! @BrendonStilesMD I don't know that there's been as much buzz on RT+anti-angiogenic therapy - though there is a published study looking at it https://t.co/wfvxSbqMWP #lcsm #radonc |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily Busy and high yield! #lcsm |
 | MD Anderson Cancer Center @MDAndersonNews A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: https://t.co/0wSgAgIsv8 #CancerMoonshot #lcsm #endcancer https://t.co/eQtUcjc7EU |
| Brendon Stiles @BrendonStilesMD T4. Yes!!! Should be considered as standard for IIIB and unresectable IIIA. #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @peggyddennis @BrendonStilesMD That's great! @BrendonStilesMD I don't know that there's been as much buzz on RT+anti-angiogenic therapy - though there is a published study looking at it https://t.co/wfvxSbqMWP #lcsm #radonc |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: It's been a while since #LCSM Chat was so busy that I couldn't keep up! Seems immunotherapy brings everyone out of the woodwork. |
| Brendon Stiles @BrendonStilesMD T4. This is based on groundbreaking PACIFIC trial from @astrazeneca https://t.co/xncbz1YCzN #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Is there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Yes!!! Should be considered as standard for IIIB and unresectable IIIA. #lcsm |
| Liz Highleyman @LizCancerHealth Is there something about the mutation itself that makes tumors less responsive to CPIs, or "colder"? #lcsm https://t.co/CDW3uKAq7G |
| H. Jack West, MD @JackWestMD @peggyddennis @BrendonStilesMD There is some scant but provocative data that pts may respond better to chemo after previously receiving immunotherapy. I've seen some vy good responses to docetaxel +/- ramucirumab after IO in some of my clinic pts...better than I'd have expected. More to learn about this. #LCSM |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD @peggyddennis @ASCO @JCO_ASCO this is still work in progress- some of the irAEs like cardiac and rheumatologic irAEs are underreported in trials- need to be vigilant while using IO agents Need to develop guidelines on how to monitor patients especially ones with pre-existing risk factors #LCSM |
| Janet Freeman-Daily @JFreemanDaily @SMImmunology @SchulichMedDent Glad you joined us! Feel free to chime in. Be sure to include #LCSM in all your tweets. |
| Brendon Stiles @BrendonStilesMD T4. Here are the progression free survival curves – favoring patients with Imfinzi (durvalumab). #lcsm https://t.co/vyu8guSTnx |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. This is based on groundbreaking PACIFIC trial from @astrazeneca https://t.co/xncbz1YCzN #lcsm |
| #LCSM Chat @lcsmchat RT @LizCancerHealth: Is there something about the mutation itself that makes tumors less responsive to CPIs, or "colder"? #lcsm https://t.co/CDW3uKAq7G |
| Brendon Stiles @BrendonStilesMD T4. Almost a 50% reduction in disease progression or death with immunotherapy. #lcsm |
| Michele @rants_by_egg Immunotherapy is keeping out of the woodwork, literally @JFreemanDaily #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @peggyddennis @BrendonStilesMD There is some scant but provocative data that pts may respond better to chemo after previously receiving immunotherapy. I've seen some vy good responses to docetaxel +/- ramucirumab after IO in some of my clinic pts...better than I'd have expected. More to learn about this. #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @BrendonStilesMD @peggyddennis @ASCO @JCO_ASCO this is still work in progress- some of the irAEs like cardiac and rheumatologic irAEs are underreported in trials- need to be vigilant while using IO agents Need to develop guidelines on how to monitor patients especially ones with pre-existing risk factors #LCSM |
 | UC Davis Comprehensive Cancer Cent @UCD_Cancer Important lung cancer news in @JAMAOnc today with a perspective from our renowned expert @drgandara. #lcsm https://t.co/mgvlNcMsu0 |
| Brendon Stiles @BrendonStilesMD T4. It is remarkable to me how many groups benefited – even those with low PD-L1 before chemoRT. #lcsm https://t.co/nRA5PMFS6p |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Here are the progression free survival curves – favoring patients with Imfinzi (durvalumab). #lcsm https://t.co/vyu8guSTnx |
| Brendon Stiles @BrendonStilesMD @JackWestMD @peggyddennis Interesting stuff. #lcsm |
 | Enlightening Results 🇵🇱❤️ 🇺🇦 @GraceCordovano RT @BrendonStilesMD: T1. Side effects are generally less than with chemotherapy, but are unique and include many “itis” problems. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Almost a 50% reduction in disease progression or death with immunotherapy. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm |
| NoRmiΞ5 @NoRmiE55 RT @BrendonStilesMD: T4. Almost a 50% reduction in disease progression or death with immunotherapy. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. It is remarkable to me how many groups benefited – even those with low PD-L1 before chemoRT. #lcsm https://t.co/nRA5PMFS6p |
| Brendon Stiles @BrendonStilesMD T4. Immunotherapy now moving into “neoadjuvant” space – treatment before surgery. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @brtmnbs @lcsmchat @JackWestMD High PDL1 doesn’t always mean the tumor 💡 are ON... PDL1 can be high just because of the mutation and not because of immune cell infiltration #LCSM |
| Denise Cutlip @dennycee If it prohibits progression yes @BrendonStilesMD: T4. there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm #lcsm |
| Enlightening Results 🇵🇱❤️ 🇺🇦 @GraceCordovano RT @BrendonStilesMD: T4. It is remarkable to me how many groups benefited – even those with low PD-L1 before chemoRT. #lcsm https://t.co/nRA5PMFS6p |
| Brendon Stiles @BrendonStilesMD T4. After just 2 doses of Nivolumab (@bmsnews), 45% of tumors had major response! https://t.co/yDjGna2sOT #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD T4. Don't patients remain on the drug for a year? So is durvalumab oncostatic or synergistic? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD We will find out with neoadjuvant clinical trials. Also adjuvant arm of ALCHEMIST #LCSM https://t.co/0PXkyNpVG0 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Immunotherapy now moving into “neoadjuvant” space – treatment before surgery. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @brtmnbs @lcsmchat @JackWestMD High PDL1 doesn’t always mean the tumor 💡 are ON... PDL1 can be high just because of the mutation and not because of immune cell infiltration #LCSM |
| #LCSM Chat @lcsmchat RT @dennycee: If it prohibits progression yes @BrendonStilesMD: If it prohibits progression yes @BrendonStilesMD: T4. there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm #lcsm |
| Brendon Stiles @BrendonStilesMD @subatomicdoc I am thinking both. #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we determine that we weren't supposed to use that word? 😉). But just like in the stage IV setting, it's not for everyone #LCSM https://t.co/FnTVGQV6il |
| Brendon Stiles @BrendonStilesMD T4. This strategy may lead to cures! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. After just 2 doses of Nivolumab (@bmsnews), 45% of tumors had major response! https://t.co/yDjGna2sOT #lcsm |
| KC Dill @kasedill Fast and furious tonight. Lots of great info!! #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @BrendonStilesMD T4. Don't patients remain on the drug for a year? So is durvalumab oncostatic or synergistic? #lcsm |
 | Jorge Luis Lopez Esq @lopezgovlaw RT @MDAndersonNews: A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: https://t.co/0wSgAgIsv8 #CancerMoonshot #lcsm #endcancer https://t.co/eQtUcjc7EU |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: We will find out with neoadjuvant clinical trials. Also adjuvant arm of ALCHEMIST #LCSM https://t.co/0PXkyNpVG0 |
| #LCSM Chat @lcsmchat RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we determine that we weren't supposed to use that word? 😉). But just like in the stage IV setting, it's not for everyone #LCSM https://t.co/FnTVGQV6il |
| NoRmiΞ5 @NoRmiE55 @BrendonStilesMD should you reverse or stop treatment if heading towards the latter? #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH |
| Dr. David Tom Cooke @DavidCookeMD "Game-changer" should be banned from #SoME #LCSM https://t.co/fVIJvWnnaq |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH |
| Brendon Stiles @BrendonStilesMD @LeciaSequist As moderator I get to make rules. "Game-changer" totally allowed. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti #personalized immunotherapy- Need scientifically rationale and innovative #biomarker trials- significant challenges to use IO agents from different pharma #LCSM need more @theNCI and cooperative grp @SWOG @eaonc funding |
| Lecia Sequist, MD, MPH @LeciaSequist For me, one of the most interesting things about neoadj IO trials is the disconnect between radiographic shrinkage and tumor cell death pathologically. It reminds us that there is a lot we still don't know when we assess our pts clinically #LCSM https://t.co/Mz3RZPrKlr |
| Krishna Soujanya Gunturu MD @kgunturuMD T1. Cardiotoxicity (CT) data is just emerging and so far there are only data from studies already done or from registry data looking at CT. CT is real and we are seeing more, but not very common #LCSM https://t.co/p1zhUQ5sP8 |
| Brendon Stiles @BrendonStilesMD T4. At @weillcornell @meyerCancer we have a trial using non-ablative SBRT + Imfinzi prior to surgery that is looking good!!! @astrazeneca #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat |
| Faces of Lung Cancer @LungCancerFaces @LeciaSequist I. Love. You. That is all. 😂 #lcsm |
| Dr. David Tom Cooke @DavidCookeMD Ok, then I am a "Change-agent". #LCSM |
| Enlightening Results 🇵🇱❤️ 🇺🇦 @GraceCordovano Saying hello to #lcsm! Exciting discussion, will catch up on the discussion if the troops ever go to bed 😂 #Parenting #WomenInHealthcare |
| Liz Highleyman @LizCancerHealth RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we determine that we weren't supposed to use that word? 😉). But just like in the stage IV setting, it's not for everyone #LCSM https://t.co/FnTVGQV6il |
| Vamsi Velcheti, MD @VamsiVelcheti Clinical trialists shd proactively engage sponsors to amend protocols to adapt trials by flexible “real-time” control arms?? Really need some level of adaptability..It would be a statistical challenge ‘nightmare’ but need innovation in study design here #LCSM @lcsmchat |
| Enlightening Results 🇵🇱❤️ 🇺🇦 @GraceCordovano RT @JackWestMD: @peggyddennis @BrendonStilesMD There is some scant but provocative data that pts may respond better to chemo after previously receiving immunotherapy. I've seen some vy good responses to docetaxel +/- ramucirumab after IO in some of my clinic pts...better than I'd have expected. More to learn about this. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. At @weillcornell we have trial using non-ablative SBRT + Imfinzi prior to surgery-looking good!!! @astrazeneca #lcsm |
| Kathleen Skambis @KathleenSkambis RT @JFreemanDaily: T4: T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. This strategy may lead to cures! #lcsm |
| Kathleen Skambis @KathleenSkambis RT @BrendonStilesMD: T4. Immunotherapy now moving into “neoadjuvant” space – treatment before surgery. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH |
| Liz Highleyman @LizCancerHealth RT @BrendonStilesMD: T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH |
| Brendon Stiles @BrendonStilesMD @VamsiVelchev @IASLC @ASCO @lcsmchat Definitely a critical issue moving forward. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: For me, one of the most interesting things about neoadj IO trials is the disconnect between radiographic shrinkage and tumor cell death pathologically. It reminds us that there is a lot we still don't know when we assess our pts clinically #LCSM https://t.co/Mz3RZPrKlr |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @LeciaSequist As moderator I get to make rules. "Game-changer" totally allowed. #lcsm |
| Saman Maleki, PhD @SMImmunology The abscopal effect happens when radiation induces an anti-tumor immune response that can destroy tumor cells outside the field of radiation. Abscopal effect is rare since radiation also induces multiple immune inhibitory mechanisms such as TGFb activation #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: #personalized immunotherapy- Need scientifically rationale and innovative #biomarker trials- significant challenges to use IO agents from different pharma #LCSM need more @theNCI and cooperative grp @SWOG @eaonc funding |
| #LCSM Chat @lcsmchat RT @LeciaSequist: For me, one of the most interesting things about neoadj IO trials is the disconnect between radiographic shrinkage and tumor cell death pathologically. It reminds us that there is a lot we still don't know when we assess our pts clinically #LCSM https://t.co/Mz3RZPrKlr |
| Vamsi Velcheti, MD @VamsiVelcheti Also it is critical to relaxing inclusion/exclusion criteria to reflect more “real world” demographics and also will help speed up patient recruitment #LCSM |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T1. Cardiotoxicity (CT) data is just emerging and so far there are only data from studies already done or from registry data looking at CT. CT is real and we are seeing more, but not very common #LCSM https://t.co/p1zhUQ5sP8 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. At @weillcornell @meyerCancer we have a trial using non-ablative SBRT + Imfinzi prior to surgery that is looking good!!! @astrazeneca #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we determine that we weren't supposed to use that word? 😉). But just like in the stage IV setting, it's not for everyone #LCSM https://t.co/FnTVGQV6il |
| Brendon Stiles @BrendonStilesMD Still lots of experts here as we move to T5. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @BrendonStilesMD W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat |
| Dr. David Tom Cooke @DavidCookeMD Do you have examples of #clincialtrials that have done this? #LCSM https://t.co/CRgpAWjmlY |
| Brendon Stiles @BrendonStilesMD T5. What else do patients want to know about immunotherapy? #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: Clinical trialists shd proactively engage sponsors to amend protocols to adapt trials by flexible “real-time” control arms?? Really need some level of adaptability..It would be a statistical challenge ‘nightmare’ but need innovation in study design here #LCSM @lcsmchat |
| Vamsi Velcheti, MD @VamsiVelcheti #LCSM @LungMAP @DrRoyHerbstYale @SWOG is a great example of innovative trial design w/multiple arms- indications and combinations w/ possibility to registration #precisionmedicine #innovation #Immunotherapy |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. At @weillcornell we have trial using non-ablative SBRT + Imfinzi prior to surgery-looking good!!! @astrazeneca #lcsm |
| #LCSM Chat @lcsmchat RT @SMImmunology: The abscopal effect happens when radiation induces an anti-tumor immune response that can destroy tumor cells outside the field of radiation. Abscopal effect is rare since radiation also induces multiple immune inhibitory mechanisms such as TGFb activation #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: Also it is critical to relaxing inclusion/exclusion criteria to reflect more “real world” demographics and also will help speed up patient recruitment #LCSM |
| Brendon Stiles @BrendonStilesMD @GraceCordovano Glad you popped in! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. What else do patients want to know about immunotherapy? #lcsm |
| Liz Highleyman @LizCancerHealth RT @VamsiVelchev: @BrendonStilesMD W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: #LCSM @LungMAP @DrRoyHerbstYale @SWOG is a great example of innovative trial design w/multiple arms- indications and combinations w/ possibility to registration #precisionmedicine #innovation #Immunotherapy |
| Brendon Stiles @BrendonStilesMD T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.co/BoxM9hMFft #lcsm |
| Michele @rants_by_egg T5 How long will it last? #lcsm |
 | Miami Gives @MiamiGives RT @MDAndersonNews: A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: https://t.co/0wSgAgIsv8 #CancerMoonshot #lcsm #endcancer https://t.co/eQtUcjc7EU |
| Lecia Sequist, MD, MPH @LeciaSequist @VamsiVelchev @lcsmchat this sounds like it could be a statistical nightmare, but I agree - almost all trials these days have an "obsolete" comparison arm by the time they read out. Thoughts @SuzDahlberg ? #LCSM |
| Brendon Stiles @BrendonStilesMD T5. Still need to define better markers or response. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Yes, I have metastatic oncogene-driven #lungcancer, but now we have targeted therapy so I can live with cancer as a chronic illness (5 years and counting). #LCSM https://t.co/pkaHCLrPi7 |
| Krishna Soujanya Gunturu MD @kgunturuMD T4. It would be interesting to see what would be relevant endpoints for neoadjuvang and how the tumor microenvironment looks like after new adjuvant therapy #lcsm https://t.co/g8jXC3Y7yI |
| Dr. David Tom Cooke @DavidCookeMD The billion dollar question, #LCSM https://t.co/RDqVVp4veq |
| Peggy Dennis @peggyddennis @BrendonStilesMD T5 - Will it work on MY cancer. That's what we all want to know. Confusing data just in the past 2 years. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.co/BoxM9hMFft #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @VamsiVelchev @lcsmchat this sounds like it could be a statistical nightmare, but I agree - almost all trials these days have an "obsolete" comparison arm by the time they read out. Thoughts @SuzDahlberg ? #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Still need to define better markers or response. #lcsm |
| Brendon Stiles @BrendonStilesMD @rants_by_egg Great question. New article in @JCO_ASCO showing 5 year survival 16%. Hopefully, we can do better. #lcsm |
| colleen ziegler @ZieglerColleen RT @peggyddennis: @BrendonStilesMD T5 - Will it work on MY cancer. That's what we all want to know. Confusing data just in the past 2 years. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD A5 How long should I take the drug? #LCSM |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T4. It would be interesting to see what would be relevant endpoints for neoadjuvang and how the tumor microenvironment looks like after new adjuvant therapy #lcsm https://t.co/g8jXC3Y7yI |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: The billion dollar question, #LCSM https://t.co/RDqVVp4veq |
| Brendon Stiles @BrendonStilesMD @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm |
 | Lee @TheNJIvoryGirl RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX |
| Lee @TheNJIvoryGirl RT @dennycee: Excellent question RT @peggyddennis: Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM |
| #LCSM Chat @lcsmchat RT @peggyddennis: @BrendonStilesMD T5 - Will it work on MY cancer. That's what we all want to know. Confusing data just in the past 2 years. #lcsm |
| Lee @TheNJIvoryGirl RT @BrendonStilesMD: T3: T3: Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @rants_by_egg Great question. New article in @JCO_ASCO showing 5 year survival 16%. Hopefully, we can do better. #lcsm |
| Paula Ashton @paulalv RT @JFreemanDaily: Yes, I have metastatic oncogene-driven #lungcancer, but now we have targeted therapy so I can live with cancer as a chronic illness (5 years and counting). #LCSM https://t.co/pkaHCLrPi7 |
| Lee @TheNJIvoryGirl RT @n8pennell: T2: T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in very very ill patients who might benefit from hospice for example #lcsm |
| Lee @TheNJIvoryGirl RT @JFreemanDaily: T1: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm |
| Brendon Stiles @BrendonStilesMD @peggyddennis But difficult even for doctors to know. Still much to learn. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm |
| H. Jack West, MD @JackWestMD Sorry folks, got pulled away...I need to cut out, but great to participate on topic so rapidly changing and giving patients so many new options that are changing what we see as possible for lung cancer & many other cancers. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @JackWestMD: Sorry folks, got pulled away...I need to cut out, but great to participate on topic so rapidly changing and giving patients so many new options that are changing what we see as possible for lung cancer & many other cancers. #LCSM |
| Brendon Stiles @BrendonStilesMD @RedGia That is a great point and something we can push for. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T5: If I am treated with an immunotherapy and it stops working, can I take a different immunotherapy later? #lcsm |
| NoRmiΞ5 @NoRmiE55 @BrendonStilesMD #LCSM how to treat side effects.. rn it’s just take some Tylenol or come to the ER for a scan |
| Saman Maleki, PhD @SMImmunology Careful design of trials that can combine #radiation with agents that block radiation's immune inhibitory mechanisms have the potential of inducing more abscopal effect. However, this needs to be tailored to the type of cancer and patient #LCSM |
| Kathleen Skambis @KathleenSkambis RT @BrendonStilesMD: T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.co/BoxM9hMFft #lcsm |
| Liz Highleyman @LizCancerHealth @VamsiVelchev Luckily advocate are on it! #lcsm https://t.co/cw6nGevX0C |
| #LCSM Chat @lcsmchat RT @JackWestMD: Sorry folks, got pulled away...I need to cut out, but great to participate on topic so rapidly changing and giving patients so many new options that are changing what we see as possible for lung cancer & many other cancers. #LCSM |
| Denise Cutlip @dennycee T5: expand reopen Exceptional Responders Program to include pets who’ve done well on IO #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: If I am treated with an immunotherapy and it stops working, can I take a different immunotherapy later? #lcsm |
| Brendon Stiles @BrendonStilesMD @NoRmiE55 Great question. See new @jco_ASCO article.https://t.co/3wRrRrJu8S #lcsm |
| #LCSM Chat @lcsmchat RT @SMImmunology: Careful design of trials that can combine #radiation with agents that block radiation's immune inhibitory mechanisms have the potential of inducing more abscopal effect. However, this needs to be tailored to the type of cancer and patient #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @peggyddennis @BrendonStilesMD T5: We need better biomarkers to help us all out. On one hand, what is the harm in trying it and seeing? Little harm for most but w/ severe complications and hyperprogression in a minority, there could be harm. Clinical judgement is key, but not always accurate of course. #LCSM |
| #LCSM Chat @lcsmchat RT @LizCancerHealth: @VamsiVelchev Luckily advocate are on it! #lcsm https://t.co/cw6nGevX0C |
| #LCSM Chat @lcsmchat RT @dennycee: T5: T5: expand reopen Exceptional Responders Program to include pets who’ve done well on IO #lcsm |
| Dee Sparacio @womenofteal RT @BrendonStilesMD: @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm |
| Krishna Soujanya Gunturu MD @kgunturuMD T5. It depends on the severity of the side effect and how well recovery was. I have few patients who we rechallenged after stopping when they recovered and now continuing on immunotherapy. But in some cases it might worsen too #LCSM https://t.co/mVnf5ZfFNV |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm |
| Enlightening Results 🇵🇱❤️ 🇺🇦 @GraceCordovano RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM |
| Brendon Stiles @BrendonStilesMD Was blowing it so much my twitter account got locked! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @NoRmiE55 Great question. See new @jco_ASCO article.https://t.co/3wRrRrJu8S #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @peggyddennis @BrendonStilesMD T5: @peggyddennis @BrendonStilesMD T5: We need better biomarkers to help us all out. On one hand, what is the harm in trying it and seeing? Little harm for most but w/ severe complications and hyperprogression in a minority, there could be harm. Clinical judgement is key, but not always accurate of course. #LCSM |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: T5. It depends on the severity of the side effect and how well recovery was. I have few patients who we rechallenged after stopping when they recovered and now continuing on immunotherapy. But in some cases it might worsen too #LCSM https://t.co/mVnf5ZfFNV |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily So many trials to date have excluded anyone with a h/o prior IO, so in reality we know little about this. My experience w/ a 2nd CPI after prior other CPI is not favorable. Combo's hopefully could be more active? #LCSM |
| KC Dill @kasedill RT @JFreemanDaily: T5: T5: If I am treated with an immunotherapy and it stops working, can I take a different immunotherapy later? #lcsm |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily Wow! You are all asking the tough questions! Exactly why we need to support more research. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily So many trials to date have excluded anyone with a h/o prior IO, so in reality we know little about this. My experience w/ a 2nd CPI after prior other CPI is not favorable. Combo's hopefully could be more active? #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @JFreemanDaily Wow! You are all asking the tough questions! Exactly why we need to support more research. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @VamsiVelchev: this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM |
| Lecia Sequist, MD, MPH @LeciaSequist @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM |
| Brendon Stiles @BrendonStilesMD Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
| colleen ziegler @ZieglerColleen RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM |
| Brendon Stiles @BrendonStilesMD @LeciaSequist @LizCancerHealth @VamsiVelchev Great point. #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM |
| Sara Whitlock @sjwhitlock @VamsiVelchev I absolutely agree. Because I have history of brain Mets I think that until recently I would have been excluded #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
| Paula Ashton @paulalv RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM |
| Brendon Stiles @BrendonStilesMD Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
| Brendon Stiles @BrendonStilesMD Please share your closing thoughts! #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @BrendonStilesMD @RedGia @US_FDA is set up to track this in theory, but it is not a perfect system. #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM |
| Dee Sparacio @womenofteal @LeciaSequist @peggyddennis @BrendonStilesMD Maybe we need to study those already in trial that respond quickly and those who have hyperprogression ( and may have to leave the trial ) to see how they differ. #LCSM |
| Paula Ashton @paulalv RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD Another great chat everyone! Thanks @BrendonStilesMD #LCSM |
| Brendon Stiles @BrendonStilesMD @sjwhitlock @VamsiVelchev Who would ever exclude you?! Have they met you? Impossible. #lcsm |
| Krishna Soujanya Gunturu MD @kgunturuMD @JFreemanDaily T5 @JFreemanDaily we don’t have much data about treating with another IO after progression. May be adding chemo to IO would work. Still need answers #lcsm |
| KC Dill @kasedill RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
| Dee Sparacio @womenofteal RT @krishna_gunturu: T5. It depends on the severity of the side effect and how well recovery was. I have few patients who we rechallenged after stopping when they recovered and now continuing on immunotherapy. But in some cases it might worsen too #LCSM https://t.co/mVnf5ZfFNV |
| Brendon Stiles @BrendonStilesMD Thanks to all of the #lcsm community who joined. And BIG thanks to all of our guests tonight. Incredible turnout! #lcsm |
| #LCSM Chat @lcsmchat RT @sjwhitlock: @VamsiVelchev I absolutely agree. Because I have history of brain Mets I think that until recently I would have been excluded #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please share your closing thoughts! #lcsm |
| Janet Freeman-Daily @JFreemanDaily NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not visible in https://t.co/A2M7gY7Hvl! |
| Paula Ashton @paulalv RT @womenofteal: @LeciaSequist @peggyddennis @BrendonStilesMD Maybe we need to study those already in trial that respond quickly and those who have hyperprogression ( and may have to leave the trial ) to see how they differ. #LCSM |
| Liz Highleyman @LizCancerHealth @LeciaSequist @VamsiVelchev No indeed! #righttotry is unlikely to improve access much, but expanded trial criteria could #lcsm |
| colleen ziegler @ZieglerColleen Thank you all, lots of good information shared tonight #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @JFreemanDaily: NOTE: NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not visible in https://t.co/A2M7gY7Hvl! |
| Brendon Stiles @BrendonStilesMD @womenofteal @LeciaSequist @peggyddennis Yes. Definitely need to figure out what "hyperprogession" is and who it occurs in. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @LeciaSequist @LizCancerHealth good point! this is such a complicated topic... didn’t expect to be discussing this with patients so often... may be a good topic for the next #LCSM chat @BrendonStilesMD |
| Dee Sparacio @womenofteal RT @VamsiVelchev: this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM |
| Denise Cutlip @dennycee Closing thought: This is an exciting time to be a patient and an advocate. Unprecedented. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Thanks to @BrendonStilesMD for a great blog and engagement as tonight's #LCSM Chat moderator! See you all in the next chat! |
| Faces of Lung Cancer @LungCancerFaces Thank you @BrendonStilesMD for your thoughtful blog post, amazing preparation and skillful moderation. #lcsm |
| Paula Ashton @paulalv #LCSM great discussion tonight. Thank you @BrendonStilesMD for moderating |
| Peggy Dennis @peggyddennis @dennycee My sentiments exactly! #lcsm |
| Brendon Stiles @BrendonStilesMD What a seriously incredible group - patients, med onc, path, rad onc, surgeons, scientists, pharm. So meaningful. #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @BrendonStilesMD @RedGia @US_FDA is set up to track this in theory, but it is not a perfect system. #LCSM |
| #LCSM Chat @lcsmchat RT @womenofteal: @LeciaSequist @peggyddennis @BrendonStilesMD Maybe we need to study those already in trial that respond quickly and those who have hyperprogression ( and may have to leave the trial ) to see how they differ. #LCSM |
| #LCSM Chat @lcsmchat RT @krishna_gunturu: @JFreemanDaily T5 @JFreemanDaily we don’t have much data about treating with another IO after progression. May be adding chemo to IO would work. Still need answers #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to all of our guests tonight. Incredible turnout! #lcsm |
| Paula Ashton @paulalv RT @dennycee: Closing thought: Closing thought: This is an exciting time to be a patient and an advocate. Unprecedented. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: NOTE: NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not visible in https://t.co/A2M7gY7Hvl! |
| Kathleen Skambis @KathleenSkambis Great, great #LCSM chat. Thank you all so much for sharing and doing so with great humor and compassion. |
| #LCSM Chat @lcsmchat RT @LizCancerHealth: @LeciaSequist @VamsiVelchev No indeed! #righttotry is unlikely to improve access much, but expanded trial criteria could #lcsm |
 | Sherry Reynolds 🌟 @Cascadia RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @womenofteal @LeciaSequist @peggyddennis Yes. Definitely need to figure out what "hyperprogession" is and who it occurs in. #lcsm |
| Krishna Soujanya Gunturu MD @kgunturuMD Thank you all for a great chat tonight #lcsm |
| Brendon Stiles @BrendonStilesMD @LungCancerFaces Just got lucky that so many talented people showed up! #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @LeciaSequist @LizCancerHealth good point! this is such a complicated topic... didn’t expect to be discussing this with patients so often... may be a good topic for the next #LCSM chat @BrendonStilesMD |
| #LCSM Chat @lcsmchat RT @dennycee: Closing thought: Closing thought: This is an exciting time to be a patient and an advocate. Unprecedented. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks to @BrendonStilesMD for a great blog and engagement as tonight's #LCSM Chat moderator! See you all in the next chat! |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: Thank you @BrendonStilesMD for your thoughtful blog post, amazing preparation and skillful moderation. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: NOTE: NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not visible in https://t.co/A2M7gY7Hvl! |
| Anita Figueras @scifiknitter RT @JFreemanDaily: Thanks to @BrendonStilesMD for a great blog and engagement as tonight's #LCSM Chat moderator! See you all in the next chat! |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: What a seriously incredible group - patients, med onc, path, rad onc, surgeons, scientists, pharm. So meaningful. #lcsm |
| #LCSM Chat @lcsmchat RT @KathleenSkambis: Great, great #LCSM chat. Thank you all so much for sharing and doing so with great humor and compassion. |
| Brendon Stiles @BrendonStilesMD @krishna_gunturu Thanks for joining! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: What a seriously incredible group - patients, med onc, path, rad onc, surgeons, scientists, pharm. So meaningful. #lcsm |
| Brendon Stiles @BrendonStilesMD @sjwhitlock @VamsiVelchev Love right back at you! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Thanks everyone for a great chat! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @LungCancerFaces @BrendonStilesMD Yes, thanks Brendon! Thanks to everyone who share their thoughts and experience tonight as well #lcsm |
| Brendon Stiles @BrendonStilesMD @womenofteal @JFreemanDaily Thanks for joining! #lcsm |
| Brendon Stiles @BrendonStilesMD @subatomicdoc @LungCancerFaces Thanks for joining! #lcsm |
| NoRmiΞ5 @NoRmiE55 RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E |
| Brendon Stiles @BrendonStilesMD @jfowlerpharmd This one was tough to keep up with. Barely managed to get the snarky stuff in! #lcsm |
| Peggy Dennis @peggyddennis RT @LungCancerFaces: Thank you @BrendonStilesMD for your thoughtful blog post, amazing preparation and skillful moderation. #lcsm |
| Brendon Stiles @BrendonStilesMD @kasedill Thanks for joining! #lcsm |
| Dr. David Tom Cooke @DavidCookeMD I suggest that patients and families take the transcript from this #immunotherapy @lcsmchat chat and use it as a study aid! #LCSM |
| Brendon Stiles @BrendonStilesMD @RedGia Thanks for participating! #lcsm |
| Brendon Stiles @BrendonStilesMD @marklewismd Indeed. Thanks for that. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @LeciaSequist Aha! I just figured it out. "CPI" means "checkpoint inhibitor," a specific type of immunotherapy. Now I can go to sleep tonight. ;) #LCSM |
| Brendon Stiles @BrendonStilesMD Good night everyone!!! Thanks. Keep working for our lung cancer community. #lcsm |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne #lcsm Thank you all for this informative online gathering. |
 | Judith Martin @judithemartin RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E |
 | Dennis Deruelle, MD @Drderuelle RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
 | John @joltdude RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM |
 | Pablo Pérez Castro, MD, FACS @pabloperezc RT @DavidCookeMD: A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM |
 | Omalkhaire Alshaikh(أمل) @alshaikh28 RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E |
| Janet Freeman-Daily @JFreemanDaily Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ |
| Pablo Pérez Castro, MD, FACS @pabloperezc RT @BrendonStilesMD: T2. For patients with PD-L1 expression >50%, Keytruda monotherapy (@merck) is indicated for both adeno and squamous #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @JFreemanDaily: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ |
| Pablo Pérez Castro, MD, FACS @pabloperezc RT @BrendonStilesMD: T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.co/BoxM9hMFft #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ |
 | Shikha Jain MD, FACP @ShikhaJainMD I missed out on the live #lcsm chat tonight! Will have to go through and see what I missed later tonight. I heard it was a good one! @lcsmchat |
 | Joe Baber @JoeBaber1 RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy |
 | Huren Sivaraj @HSivarajMD RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we determine that we weren't supposed to use that word? 😉). But just like in the stage IV setting, it's not for everyone #LCSM https://t.co/FnTVGQV6il |
 | conciergedoc @DrFerdowsi RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm |
#LCSM content from Twitter.